Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 25, 2018
Targets & Mechanisms
Blueprint for selectivity
Why Blueprint thinks its selective ALK2 inhibition is the best bet for treating FOP
BioCentury | Feb 9, 2018
Emerging Company Profile
Fast boat to China
Abbisko aims to be first to market in China with ‘me better’ cancer compounds
BioCentury | Nov 10, 2017
Product R&D
Blueprint gets the GIST
How Blueprint’s BLU-285 targets mutant kinases resistant to front-line drugs
Items per page:
1 - 10 of 17